Teriflunomide (Aubagio) approved for treatment of MS in the US
17th September, 2012
The effect of teriflunomide on relapse rates is slightly below that of beta interferon treatments, but it has a better side effects profile and removes the requirement for injection. There is an increased risk of liver problems for people taking teriflunomide and the approval comes with a requirement for a boxed warning for prescribers and patients and a recommendation that ongoing liver tests are performed.
Teriflunomide acts by blocking the proliferation and functioning of activated T and B lymphocytes, immune cells which are thought to be especially damaging in MS.
MSRA understands teriflunomide will be undergoing assessment for approval by the Australian Therapeutic Goods Administration (TGA) and Pharmaceutical Benefits Advisory Council (PBAC) in Australia within the next month. MSRA welcomes this progress towards another treatment choice for people with MS.